RASGEF1B

Across TCGA pan-cancer cohorts, RASGEF1B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RASGEF1B data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RASGEF1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RASGEF1B expression acts as an unfavorable survival marker.

CESC, COAD, and KICH are the cancer types where RASGEF1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.144	0.705	.004	18	view →
COAD	OS	Median	All	0.168	0.799	.004	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUAD	DFS	Median	All	0.098	0.768	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RASGEF1B–CESC (DFS)

Open the CESC breakdown →